Marinos C. Dalakas MDProfessor of Neurology, and Chief, Neuromuscular Division, Thomas Jefferson University, Philadelphia, Pennsylvania; Chief, Neuroimmunology Unit, National and Kapodistrian University of Athens, Athens, Greece
Dr. Marinos Dalakas is Professor of Neurology and Director of the Neuromuscular Division at Thomas Jefferson University School of Medicine in Philadelphia. He is Professor of Neurology and Chief of the Neuroimmunology Laboratory in the Department of Pathophysiology at the University of Athens Medical School in Athens, where he has been Emeritus Professor since 2016. Dr. Dalakas is an appointed member in various scientific societies and is a member of the American Neurological Association, the American Academy of Neurology, the European Neurological Society, and the International Society of Greek Neuroscientists, among other professional organizations.
Dr. Dalakas has published widely. His areas of research are broad and include neuroimmunology, neurovirology, immunogenetics, and immunotherapies in neurologic diseases. He has focused on immunopathogenesis of autoimmune neuropathies and myopathies, stiff-person syndrome and autoimmune hyper-excitability CNS disorders, and other autoimmune neurological disorders including multiple sclerosis, myelitis and amyloidosis. He has conducted several controlled clinical trials including the first with intravenous Immunoglobulin (IVIg) in autoimmune neurology.
He completed a 3-year fellowship training in neuromuscular diseases at the Medical Neurology Branch of the NINCDS in Bethesda, Maryland and an additional 5-year training in Neuroimmunology/Neurovirology at NINDS. He subsequently served as Chief of the Neuromuscular Diseases Section of the NINDS, NIH, a position he held for 20 years before joining Thomas Jefferson University.
Marinos C. Dalakas, MD, serves on the Scientific Advisory Board or has received speaking honoraria the last 2 years from: Sanofi, Octapharma, Grifols, Argenx, DDF, Alexion and UCB. He has received honoraria from TAND (Therapeutic Advances in Neurological Disorders), from N2 (Neurology, Neuroimmunology, Neuroinflammation) and from Neurodiem for serving as Associate Editor. He has received institutional grant support to Thomas Jefferson University or the University of Athens Medical School from Dysimmune Diseases Foundation, Newfactor, Infucare, Merck-Serono, and Novartis.
Recent Contributions to PracticeUpdate:
- 2023 Top Story in Neurology: Long-COVID Muscle Fatigue—A Common Multifactorial Symptom Without Muscle-Specific Pathophysiology
- Therapeutic Plasma Exchange in the Management of Stiff Person Syndrome Spectrum Disorders
- Myopathy as a Cause of Long COVID Fatigue
- 2022 Top Story in Neurology: Is the Fatigue in “Prolonged Long COVID” Related to Myopathy? No Convincing Evidence
- Treating Chronic Inflammatory Demyelinating Polyneuropathy With Three IVIg Doses
- 2021 Top Story in Neurology: Neuromuscular Disease—Unconvincing Evidence for COVID-Associated Myositis
- Efgartigimod Shows Efficacy and Safety in Generalised Myasthenia Gravis
- 2020 Top Stories in Neurology: Rituximab Treatment for New-Onset Generalized Myasthenia Gravis: Promising Effects for Long-Term Remission
- Contactin-1 Autoimmunity
- Neurologic Syndromes Related to Anti-GAD65